Amylyx Pharmaceuticals, Inc. Revenue
Amylyx Pharmaceuticals, Inc. (AMLX) reported Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-03-03
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00.
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $87.37M, a 77.06% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $380.79M, a 1612.94% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $22.23M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$665.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | -$665.00K derived: sum of 3 quarters · filed 2026-03-03 | -$249.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$665.00K derived: sum of 2 quarters · filed 2026-03-03 | -$249.00K derived: sum of 3 quarters · filed 2026-03-03 | -$1.27M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | -$665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$249.00K derived: sum of 2 quarters · filed 2026-03-03 | -$1.27M derived: sum of 3 quarters · filed 2026-03-03 | $87.37M 10-K · filed 2026-03-03 |
| 2024-09-30 | $416.00K 10-Q · filed 2025-11-06 | -$607.00K derived: sum of 2 quarters · filed 2025-11-06 | $88.04M 10-Q · filed 2025-11-06 | $196.49M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.02M 10-Q · filed 2025-08-07 | $87.62M 10-Q · filed 2025-08-07 | $196.07M derived: sum of 3 quarters · filed 2025-08-07 | $298.76M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $88.64M 10-Q · filed 2025-05-08 | $197.09M derived: sum of 2 quarters · filed 2025-05-08 | $299.79M derived: sum of 3 quarters · filed 2025-05-08 | $398.00M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $108.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $211.14M derived: sum of 2 quarters · filed 2025-03-04 | $309.36M derived: sum of 3 quarters · filed 2025-03-04 | $380.79M 10-K · filed 2025-03-04 |
| 2023-09-30 | $102.69M 10-Q · filed 2024-11-07 | $200.91M derived: sum of 2 quarters · filed 2024-11-07 | $272.34M 10-Q · filed 2024-11-07 | $294.22M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $98.22M 10-Q · filed 2024-08-08 | $169.64M 10-Q · filed 2024-08-08 | $191.53M derived: sum of 3 quarters · filed 2024-08-08 | $191.87M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $71.43M 10-Q · filed 2024-05-09 | $93.31M derived: sum of 2 quarters · filed 2024-05-09 | $93.66M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $21.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $22.23M derived: sum of 2 quarters · filed 2024-02-22 | $22.23M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $345.00K 10-Q · filed 2023-11-09 | $345.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |